<DOC>
	<DOC>NCT01470326</DOC>
	<brief_summary>In this survey, to collect the safety and efficacy information of Bazedoxifene in daily medical practice will be examined. In addition, the necessity of special Investigation and post-marketing clinical studies will be examined, while investigating unexpected adverse drug reactions during the survey period and understanding of the status of frequency of adverse drug reactions in daily medical practice.</brief_summary>
	<brief_title>Viviant 20mg Special Investigation (Regulatory Post Marketing Commitment Plan)</brief_title>
	<detailed_description>All the subjects whom an investigator prescribes the first Bazedoxifene (Viviant) Tablets should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bazedoxifene</mesh_term>
	<criteria>Post menopausal women subjects with Osteoporosis who has no experience of use of Bazedoxifene. Subject with present or past venous thromboembolism such as deep venous thrombosis, pulmonary embolism, or retinal venous thrombosis Subject in longterm immovability (postoperative recovery, longterm bed rest) Subject with antiphospholipid antibody syndrome</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>Post menopausal women</keyword>
	<keyword>SERM</keyword>
	<keyword>Japanese</keyword>
	<keyword>Viviant</keyword>
	<keyword>Regulatory Post Marketing Commitment Plan</keyword>
	<keyword>Long term treatment</keyword>
</DOC>